➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School

Last Updated: June 25, 2021

DrugPatentWatch Database Preview

GEMTESA Drug Profile

Email this page to a colleague

« Back to Dashboard

When do Gemtesa patents expire, and when can generic versions of Gemtesa launch?

Gemtesa is a drug marketed by Urovant and is included in one NDA. There are two patents protecting this drug.

This drug has fifty-four patent family members in thirty-nine countries.

The generic ingredient in GEMTESA is vibegron. Additional details are available on the vibegron profile page.

DrugPatentWatch® Generic Entry Outlook for Gemtesa

Gemtesa will be eligible for patent challenges on December 23, 2024. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 1, 2030. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Get Started Free

Summary for GEMTESA
International Patents:54
US Patents:2
What excipients (inactive ingredients) are in GEMTESA?GEMTESA excipients list
DailyMed Link:GEMTESA at DailyMed
Drug patent expirations by year for GEMTESA
DrugPatentWatch® Estimated Generic Entry Opportunity Date for GEMTESA
Generic Entry Date for GEMTESA*:
Constraining patent/regulatory exclusivity:

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for GEMTESA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Urovant GEMTESA vibegron TABLET;ORAL 213006-001 Dec 23, 2020 RX Yes Yes   Get Started Free   Get Started Free Y Y   Get Started Free
Urovant GEMTESA vibegron TABLET;ORAL 213006-001 Dec 23, 2020 RX Yes Yes   Get Started Free   Get Started Free Y   Get Started Free
Urovant GEMTESA vibegron TABLET;ORAL 213006-001 Dec 23, 2020 RX Yes Yes   Get Started Free   Get Started Free   Get Started Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.